Roivant Sciences Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Incyte Corp.

Alnylam Pharmaceuticals, Inc.

Repligen Corp.

Neurocrine Biosciences, Inc.

United Therapeutics Corp.

Royalty Pharma Plc

Sarepta Therapeutics, Inc.

Roivant Sciences Ltd.

Walgreens Boots Alliance, Inc.

Viatris, Inc.

Horizon Therapeutics Plc

Why is Roivant Sciences Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of -22.08% and Operating profit at -390.27% over the last 5 years

The company has declared negative results for the last 2 consecutive quarters

OPERATING CASH FLOW(Y) Lowest at USD -851 MM
DEBTORS TURNOVER RATIO(HY) Lowest at 0.22 times
INVENTORY TURNOVER RATIO(HY) Lowest at 0.31 times

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 67.42%, its profits have fallen by -117.5%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Roivant Sciences Ltd. for you?

Medium Risk, High Return

Absolute

Risk Adjusted

Volatility

Roivant Sciences Ltd.

74.75%

3.01

32.24%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-22.08%

EBIT Growth (5y)

-390.27%

EBIT to Interest (avg)

-138.40

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.04

Sales to Capital Employed (avg)

0.03

Tax Ratio

8.26%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

89.46%

ROCE (avg)

ROE (avg)

19.26%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.63

EV to EBIT

-2.43

EV to EBITDA

-2.45

EV to Capital Employed

-14.36

EV to Sales

36.15

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-17.21%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

NET PROFIT(HY)

Higher at USD -435.4 MM

RAW MATERIAL COST(Y)

Fallen by -17.26% (YoY

-29What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -851 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 0.22 times

INVENTORY TURNOVER RATIO(HY)

Lowest at 0.31 times

NET SALES(Q)

Lowest at USD 2.17 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -13,079.45 %

PRE-TAX PROFIT(Q)

At USD -247.81 MM has Fallen at -26.74%

NET PROFIT(Q)

At USD -201.9 MM has Fallen at -29.81%

EPS(Q)

Lowest at USD -0.33

Here's what is working for Roivant Sciences Ltd.

Raw Material Cost

Fallen by -17.26% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Roivant Sciences Ltd.

Net Sales

At USD 2.17 MM has Fallen at -88.61%

over average net sales of the previous four periods of USD 19.05 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Debtors Turnover Ratio

Lowest at 0.22 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Operating Cash Flow

Lowest at USD -851 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Net Sales

Lowest at USD 2.17 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Operating Profit Margin

Lowest at -13,079.45 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

At USD -247.81 MM has Fallen at -26.74%

over average net sales of the previous four periods of USD -195.52 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -201.9 MM has Fallen at -29.81%

over average net sales of the previous four periods of USD -155.53 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD -0.33

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Inventory Turnover Ratio

Lowest at 0.31 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio